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Abstract
Biomarker identification is of utmost importance for the development of novel diagnostics and therapeutics. Here we make
use of a translational database selection strategy, utilizing data from the Human Protein Atlas (HPA) on differentially expressed
protein patterns in healthy and breast cancer tissues as a means to filter out potential biomarkers for underlying genetic
causatives of the disease. DNA was isolated from ten breast cancer biopsies, and the protein coding and flanking non-coding
genomic regions corresponding to the selected proteins were extracted in a multiplexed format from the samples using a
single DNA sequence capture array. Deep sequencing revealed an even enrichment of the multiplexed samples and a great
variation of genetic alterations in the tumors of the sampled individuals. Benefiting from the upstream filtering method, the
finalsetofbiomarker candidatescouldbecompletely verified throughbidirectionalSangersequencing, revealinga 40percent
false positive rate despite high read coverage. Of the variants encountered in translated regions, nine novel non-synonymous
variations were identified and verified, two of which were present in more than one of the ten tumor samples.
Citation: Sta ˚hl PL, Bjursell MK, Mahdessian H, Hober S, Jirstro ¨m K, et al. (2011) Translational Database Selection and Multiplexed Sequence Capture for Up Front
Filtering of Reliable Breast Cancer Biomarker Candidates. PLoS ONE 6(6): e20794. doi:10.1371/journal.pone.0020794
Editor: Vladimir N. Uversky, University of South Florida College of Medicine, United States of America
Received March 2, 2011; Accepted May 11, 2011; Published June 15, 2011
Copyright:  2011 Sta ˚hl et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Knut and Alice Wallenberg Foundation (www.wallenberg.com/kaw), the Swedish Cancer Foundation (www.
cancerfonden.se) and the Swedish Scientific Council (www.vr.se). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: patrik.stahl@scilifelab.se
Introduction
Discovery of biomarkers has traditionally been mediated by
interpretation of transcriptome data generated using array-based
expression profiling platforms [1,2]. Thishas for instance resulted in
better understanding of prostate cancers, where the initial screening
for serum PSA has led to earlier detection of the disease, but also to
inaccurate diagnosis, necessitating discovery of new and better
biomarkers [3,4]. It has earlier been shown that biomarker dis-
covery benefits from integration of genomic and proteomic techno-
logies [5]. Recent data have also demonstrated a stronger corre-
lation between transcripts and proteins than previously anticipated
[6,7]. Thus, translating aberrant protein expression patterns to
transcript differencesis of highinterest, and the possibilitythat some
of these changes are encoded in the genome offers new openings to
identify causative mutations. Today’s novel technologies and large-
scale efforts for proteomic screening are providing the grounds for a
great increase of pace in such biomarker discovery. The Human
Protein Atlas is one example where the proteome is being screened
for differences in expression patterns in a large collection of cancers
and corresponding healthy tissues [8,9]. Antibodies are created for
each human protein in a mono-specific polyclonal fashion and are
used to stain tissue microarrays in order to determine the expression
patterns and levels.
In addition to more efficient proteomic screening, the advent of
massively parallel sequencing methods [10,11,12] has greatly
increased the throughput of genomic data [13] and has also
provided new platforms for transcriptomic screening past the
traditional array based technologies [14,15]. Whereas genomes of
healthy and diseased tissues can be sequenced in full today [16,17],
the sequencing throughput is still not able to provide us with
enough data to screen vast numbers of genomes in parallel in a
cost-efficient manner. The response to this has traditionally been
selection of genomic regions of interest by PCR [18], but has lately
been replaced by methods for extraction of regions of interest by
sequence enrichment strategies [19,20,21].
Here we demonstrate a model for further cost reduction and
increased efficiency in biomarker discovery by employing up-front
database selection in combination with sample barcoding [22] and
multiplexed sequence capture enrichment, to rationally filter out
potential biomarkers at an early stage.
Materials and Methods
Ethics statement
Ethical permission was obtained from the Ethics Committee at
Lund University whereby informed consent was deemed not to be
required other than by the opt-out method. The study was
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data were analyzed anonymously.
Translational database selection
The Human Protein Atlas database [8] was searched for pro-
teins with a clearly differential staining pattern in healthy breast
tissue and breast cancer tissue requiring: i) breast glandular cells
with no staining and ii) breast cancer tumor cells with at least five
patients with strong staining. A complementary search for breast
glandular cells with strong staining and breast cancer tumor cells
with at least ten patients with weak or no staining was also carried
out.
Further, the proteins found through the search results were
screened to match a number of criteria of interest. These included
overall differential staining of healthy and cancerous tissues for the
particular protein and high assay validation scores. Proteins were
scored as particularly interesting if they were present in a trans-
membrane region, and if they contained a signaling peptide. In
total, 41 proteins were selected in this way and an additional 10
proteins known to be associated with cancer from the literature
were added to the list. (Table S1)
Selection and design of regions for genomic enrichment
The coding exons for the proteins selected through the HPA
database were extracted from the UCSC human reference genome
(hg18) database. Additionally the 59UTR and 39UTR regions
were included, as well as 1000 basepairs upstream from the 59UTR.
To facilitate efficient capture of the targeted genomic regions, the
selected regions were expanded to a minimum of 250 basepairs and
regions with a resulting overlap were fused together. 479 regions
totaling 303,788 basepairs, 89,705 of which were protein coding,
were selected in this way.
The selected regions were submitted to the array manufac-
turer (Nimblegen, Madison, WI, USA) for manufacturing of
385k-feature enrichment arrays. The final design after internal
processing and filtering of repetitive regions contained 581 tiled
regions spanning a total of 303,986 target bases.
Sampling of tumors and DNA extraction
Tumors were surgically removed from the patients, trimmed for
healthy tissue and instantly put into a freezer at 220uC. .99% of
the cells were judged to be of tumor origin. For extraction of DNA
ten pieces approximately 1 mm
3 each were cut out from each
tumor and put into a fastprep tube (164102930, Lysing matrix D,
Fisher Scientific, Gothenburg, Sweden). 360 ml of ATL buffer
from the DNeasy (Qiagen, Valencia, CA, USA) kit was added to
the tube that was then processed 2 times 60 seconds on a Fastprep
FP210 system (Qbiogene, Carlsbad, CA, USA). The homogenized
liquid phase was pipetted into a Qiashredder column (Qiagen,
Valencia, CA, USA) that was centrifuged for 1 minute at 13k rpm.
40 ml of proteinase K (Qiagen, DNeasy kit) was added to the
shredded material followed by a 15-minute incubation of the
sample at 56uC. 300 ml of buffer AL (DNeasy, Qiagen) and 300 ml
96% ethanol was added to the sample and the resulting mixture
was split in half and transferred into 2 DNeasy Mini spin columns.
The columns were processed according to manufacturers instruc-
tions (DNeasy, Qiagen) after which each sample was eluted twice
with 200 ml of EB buffer (DNeasy, Qiagen) in separate tubes,
totaling 4 tubes with 200 ml eluate each for each initial tumor
sample.
Following elution each sample was ethanol precipitated by
adding 20 ml 3 M NaAc and 500 ml 220uC 96% ethanol, and
then incubated at 280uC for 15 minutes. After freezing the
sample was centrifuged at 13k rpm for 25 minutes in room
temperature. The sample was washed with 500 ml 220uC 70%
ethanol and centrifuged at 13k rpm for another 15 minutes in
room temperature. The liquid was removed and the sample tubes
were dried at room temperature over night with open lids under
a protective cover. The following day 20 ml 1xTE buffer was
added to each sample tube to dissolve the extracted DNA after
which the tubes for each sample were pooled and analyzed for
concentration and purity on a NanoDrop N-1000 spectropho-
tometer (NanoDrop, Wilmington, DE, USA).
Healthy reference tissue from each patient sample was pro-
cessed in the same way to obtain DNA for validation sequencing
of variations indicative of potential biomarkers.
DNA enrichment and sequencing
A total of ten DNA samples from breast cancer tumors were
processed into sequencing libraries using an in house developed
automated protocol [23] based on the GS FLX titanium Library
preparation method (Roche/454, Branford, CT, USA) using
multiplex identifier handles (MID 1–10, Roche/454). The samples
were then pooled in equimolar ratios into a single tube and
enriched for target sequences by hybridizing to the custom
Nimblegen 385k array (Roche/Nimblegen, Madison, WI, USA)
previously designed and manufactured for the project. Following
enrichment the pooled library was titrated and sequenced
according to manufacturers instructions (Roche/454) on a GS
FLX using long-read titanium chemistry.
Data analysis
The data corresponding to each sample was mapped to the
human reference genome (hg19) using the Roche/454 GS Mapper
software (Newbler version 2.3), and the file containing the resulting
high confidence variants (HCdiffs.txt) was used for further analysis.
The single nucleotide variants were annotated using custom perl
scripts and the knownGene transcript database (UCSC). The
variants were sorted by the number of samples they were present
in. Information from dbSNP 130 was used to extract previous
knowledge about specific SNPs.
Validation of variations
Following Roche/454 sequencing and data analysis as described
above, 15 novel non-synonymous variations were encountered,
spread across the different samples (Table S2). These were verified
through amplification by PCR followed by bidirectional Sanger
sequencing of the corresponding genomic regions. Nine out of
these variations were confirmed as heterozygous in both tumor
tissue and healthy reference tissue, whereas six of the variants were
not visible in either tissue in the validation experiments, hence
deemed false positives.
Results
DNA from breast cancer samples and surrounding healthy
breast tissue (Figure 1) was isolated from ten surgically removed
tumors and selected genes were investigated using array-based
enrichment and DNA sequencing. In total, 581 genomic regions
corresponding to the 51 selected differentially expressed or lite-
rature derived proteins (Table S1) were surveyed for mutations.
Out of the 1,109,321 sequencing reads generated, 22.63%
mapped uniquely to the human genome and overlapped with the
303,936 bases associated with the 581 target regions. Of the
generated bases, 69.3 million mapped to the target, corresponding
to an average 228 times sequence coverage of the target. .99.9%
of the target was covered by at least one read. The distribution of
reads between the different samples was good in general (Table 1)
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inefficiently amplified in the emPCR, as verified later by qPCR of
the MIDs [23], and the sample labeled with MID 9 generated very
low concentrations at the library preparation, which resulted in a
lower molar amount of DNA from the MID 9 tagged sample in
the pool.
In total 1,982 single nucleotide variations (SNVs) at 579 unique
positions in the target regions were found in the tumor samples
when compared to the human reference sequence (hg19). A higher
rate of variation, per base, was seen in 59UTR, 39UTR, promotor
and intron sequence of the target (0.07%), than in protein coding
exon sequence (0.05%). Of the 149 unique positions with SNVs in
protein coding sequence (488 SNVs total), 66 were subjected to an
amino acid change. 15 of these non-synonymous alterations had
not previously been reported in dbSNP build 130. All novel SNVs
were detected in frequencies above 20% of the reads. Six of these
non-previously reported variations were encountered in more
than one tumor sample, and were confined to three genes, one in
SATB1, four in MUC5AC and one in DDX26B (Table 2).
Confirmatory Sanger sequencing was carried out for all 15
novel SNVs in the tumor samples and normal reference tissue.
This resulted in confirmation of nine of the 15 SNVs as hete-
rozygous variations present in both tumor and normal tissue. The
six remaining variations turned out to be false positives.
Discussion
The percentage of reads mapping to the targeted regions for the
used enrichment platform has previously been reported around
60–80% [19]. There are several possible reasons for the modest
fraction of sequencing reads that mapped to the targeted regions in
Figure 1. Principle of a differentially expressed protein, as seen on the tissue array images in the Human Protein Atlas database.
Immunohistochemical staining using antibodies targeting the interrogated protein in the tissue sectionss gives rise to a localized and distinct brown
color. In the first case (top) the healthy breast tissue does not seem to show any expression of the PIP protein, whereas the breast cancer tissue shows
heavy expression of the targeted protein. In the second case (bottom) the healthy breast tissue shows heavy expression of the ACTG1 protein,
whereas the breast cancer tissue does not seem to show any expression of the targeted protein.
doi:10.1371/journal.pone.0020794.g001
Table 1. Distribution of mapped reads, bases, coverage and
variants per sample.
Sample
Mapped
reads
Mapped
bases
Ave
coverage SNVs
Coding
SNVs
MID1 35243 9.9mil 33 247 66
MID2 30264 8.6mil 28 215 50
MID3 2739 0.8mil 3 27 8
MID4 22952 6.4mil 21 217 55
MID5 30869 8.5mil 28 230 46
MID6 18608 5.2mil 17 221 63
MID7 20239 5.6mil 18 185 48
MID8 38539 10.7mil 35 252 53
MID9 7815 2.2mil 7 129 34
MID10 40046 11.4mil 38 259 65
Total 247314 69.3mil 228 1982 488
Distribution of mapped reads, bases, coverage and single nucleotide variants
(SNVs) across the ten multiplex enriched breast cancer tumor samples. An even
distribution across all samples except those tagged with multiplex identifier tag
3 and 9. Poor amplification characteristics of MID 3 was later verified by qPCR
[21] to be the reason for poor representation of the corresponding sample
among the sequence reads. The sample tagged with MID 9 was added in a
lower molar amount upon pooling due to a low DNA concentration after library
preparation.
doi:10.1371/journal.pone.0020794.t001
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expected and can be coupled to the array-design, the sequence in
the targeted regions, and the number and spread of the target
regions across the genome. From these three aspects our approach
was as difficult as possible. The design algorithm was the first
version provided by the manufacturer, the locations of the selected
target regions could be denoted as close to random and the target
region length as relatively short (average length 521 bp). It is also
feasible to believe that the multiplexing of samples on the capture
array may have influenced the result with more non-targeted
regions being able to remain close to the array surface through
binding to the handles of real target fragments hybridized to the
actual array.
To determine the usability of the results generated through the
translational selection, multiplexed enrichment and sequencing
methods, a high level of correlation to dbSNP for the non-
synonymous SNVs should give a high validity to the method
employed to find the variations. Additionally several of the non-
synonymous SNVs (66 in total; Table 2) were present in genes with
a previously established connection to breast cancer development
through inherited genetic variations such as BRCA1 (seven SNVs)
and BRCA2 (two SNVs) [24]. This together with high bidirec-
tional sequence coverage should make the nine verified non-
synonymous variations, present in normal and cancerous tissue in
their respective individuals and not previously present in dbSNP
(version 130), interesting for further analysis.
On the other hand, of the 15 non-synonymous mutations that
were encountered in the samples, six turned out to be false
positives when verified by bidirectional Sanger sequencing (Table
S2). This raises increased concerns relating to the generation
of systematic errors by present massive sequencing platforms.
Further, comparison of these six seemingly novel non-synonymous
mutations to the latest version of dbSNP (version 131) marks two
of them as previously reported. Given previous false positive results
already raising concerns to the quality of the content of dbSNP
[25], this provides even further reason to exercise care when using
the current versions of variant databases.
Two of the remaining previously unreported non-synonymous
SNVs were found in the genomes of more than one individual.
Each was verified as a heterozygous SNV present in both normal
and cancerous tissue. Their presence in SATB1, previously linked
to breast cancer promotion [26], and DDX26B, to our knowledge
previously unreferenced in relation to breast cancer, provides
further support for continued examination of the role of the genes
in conjunction to breast cancer.
Lastly, the higher frequency of variations seen in non-coding
sequence as compared to coding sequence has previously been
reported in healthy [18] and cancerous [17] tissue, strengthening
the scientific grounds for the logical reasoning that non-protein-
coding regions of the genome are less subjected to evolutionary
constraints.
In summary, the employment of a translational database selec-
tion strategy in combination with multiplexed enrichment by
sequence capture provides a tool for careful biomarker discovery.
Given the abundance of false positives generated by massive
sequencing approaches, employing a rational selection strategy
prior to sequencing can provide an efficient means to limit the
number of variants at the end of the pipeline, enabling a complete
variant verification process and a more reliable final list of
biomarker candidates.
Supporting Information
Table S1 Selected genes. 41 proteins and their corresponding
genes were selected through the HPA database and 10 more
proteins and their corresponding genes known to be associated
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Table S2 Novel non-synonymous SNVs. Among the novel
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